Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Equivalents (2016 - 2025)

Assembly Biosciences has reported Cash & Equivalents over the past 12 years, most recently at $58.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 52.44% year-over-year to $58.4 million; the TTM value through Dec 2025 reached $58.4 million, up 52.44%, while the annual FY2025 figure was $58.4 million, 52.44% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $58.4 million at Assembly Biosciences, up from $22.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $78.3 million in Q1 2021 and troughed at $18.7 million in Q1 2024.
  • A 5-year average of $40.0 million and a median of $40.7 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 62.15% in 2023 and later skyrocketed 93.26% in 2024.
  • Year by year, Cash & Equivalents stood at $45.6 million in 2021, then rose by 14.88% to $52.4 million in 2022, then crashed by 62.15% to $19.8 million in 2023, then skyrocketed by 93.26% to $38.3 million in 2024, then surged by 52.44% to $58.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for ASMB at $58.4 million in Q4 2025, $22.5 million in Q3 2025, and $24.0 million in Q2 2025.